Med LifeLTS:0RO5 75 PS Ratio is 2.48 as of Jul. 07, 2026, which is 110% above its 10-year median of 1.18. GuruFocus rates LTS:0RO5 with a GF Score™ of 75/100 and a GF Value™ of lei1.39 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 657 Healthcare Providers & Services companies, Med Life ranks worse than 67.58% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Med Life's share price is lei11.3753.
Med Life's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was lei4.59. Hence, Med Life's PS Ratio for today is 2.48.
Warning Sign:
Med Life SA stock PS Ratio (=2.81) is close to 10-year high of 2.84.
The historical rank and industry rank for Med Life's PS Ratio or its related term are showing as below:
LTS:0RO5'
s PS Ratio Range Over the Past 10 Years
Min: 0.58 Med: 1.18 Max: 2.84
Current: 2.81
During the past 11 years, Med Life's highest PS Ratio was 2.84. The lowest was 0.58. And the median was 1.18.
LTS:0RO5's PS Ratio is ranked worse than 67.58% of 657
companies
in the Healthcare Providers & Services industry
Industry Median: 1.5
vs LTS:0RO5: 2.81
Med Life's Revenue per Sharefor the
three
months ended in Mar. 2026 was lei1.61.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was lei4.59.
During the past 12 months, the average Revenue per Share Growth Rate of Med Life was 18.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 23.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 24.10% per year.
During the past 11 years, Med Life's highest 3-Year average Revenue per Share Growth Rate was 27.30% per year. The lowest was 16.40% per year. And the median was 22.60% per year.
Back to Basics: PS Ratio
Med Life (LTS:0RO5) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Med Life PS Ratio Related Terms
Med Life PS Ratio Historical Data
* Premium members only.
The historical data trend for Med Life's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Med Life's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Med Life PS Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Med Life's PS Ratio distribution charts can be found below:
* The bar in red indicates where Med Life's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Med Life's Share Price of today is lei11.3753. Med Life's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei4.59.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Med Life (LTS:0RO5) has a PS Ratio of 2.48 as of Jul. 07, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Med Life and its competitors. This is 110% above median its historical median of 1.18. Over the past decade, Med Life's PS Ratio has ranged from 0.58 to 2.84. According to the industry distribution chart, Med Life ranks #444 out of 657 companies in the Healthcare Providers & Services industry, placing it in the top 67.6%.
Is Med Life's PS Ratio too high?
Med Life's current PS Ratio of 2.48 is 110% above median its 10-year median of 1.18. Over the past 10 years, this metric has ranged from a low of 0.58 to a high of 2.84. The Healthcare Providers & Services industry median PS Ratio is 1.50. Med Life's value of 2.48 is 65.3% above this industry median. Based on the distribution chart, Med Life ranks #444 out of 657 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Med Life has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Med Life's PS Ratio compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Med Life ranks #444 out of 657 companies for PS Ratio. This places Med Life in the lower half of its industry. The industry median PS Ratio is 1.50. Med Life's value of 2.48 is 65.3% above this benchmark. Historically, Med Life's own PS Ratio has ranged from 0.58 to 2.84 over the past decade. While the company's 10-year median is 1.18 vs. the industry median of 1.50, Med Life has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Healthcare Providers & Services company?
The median PS Ratio among Healthcare Providers & Services companies is 1.50, based on 657 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Med Life's current PS Ratio of 2.48 is 65.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Med Life and its competitors. For the Healthcare Providers & Services industry, the median PS Ratio is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Med Life's current PS Ratio is 2.48, which is 110% above median its own 10-year median of 1.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Med Life stock overvalued right now?
Based on GuruFocus' analysis, Med Life (LTS:0RO5) is currently considered Significantly Overvalued. The stock's GF Value™ is lei1.39, compared to a current price of lei11.38 — trading 718.4% above its estimated fair value. The current PS Ratio is 2.48, which is 110% above median its 10-year median of 1.18 and 65.3% above the Healthcare Providers & Services industry median of 1.50. Med Life's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Med Life (LTS:0RO5), the current PS Ratio is 2.48 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Med Life (LTS:0RO5) Overvalued in 2026?
Based on GuruFocus' analysis, Med Life stock appears to be overvalued.
The current stock price of lei11.38 is trading 718.4% above its estimated GF Value™ of lei1.39.
GuruFocus considers Med Life to be Significantly Overvalued.
Key valuation signals for LTS:0RO5:
PS Ratio: 2.48 (110% above median its 10-year median of 1.18)
GF Value™: lei1.39 vs. price of lei11.38 (718.4% above fair value)
Industry Position: 65.3% above the Healthcare Providers & Services median (#444 of 657)
No single metric tells the full story. See the LTS:0RO5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Med Life SA is a healthcare provider in Romania. The Company's activity resides in the performance of healthcare services activities through medical centres with national coverage. It is engaged in the provision of rendering of medical services, rental of medical facilities and acquisition of materials and commodities. The company provides medical service through Hyper clinics in Arad, Bucharest, Braila, Brasov, Cluj, Constanta, Craiova, Galati, Iasi, Oradea, Ploiesti, Sibiu and Timisoara; Clinics, hospitals located in Bucharest, Arad, Sibiu, Brasov, Cluj and Ploiesti, Laboratories, Pharmacies and Dental Clinics.
75GF Score
Get the complete analysis for LTS:0RO5
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RO5 has been successfully added to your 
